IBEX TECHNOLOGIES INC (IBT.CA) Stock Fundamental Analysis
Canada - TSX Venture Exchange - TSX-V:IBT - CA4489375085 - Common Stock
1.44 CAD
0 (0%)
Overall IBT gets a fundamental rating of 6 out of 10. We evaluated IBT against 23 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making IBT a very profitable company, without any liquidiy or solvency issues. IBT has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
- In the past year IBT was profitable.
- IBT had a positive operating cash flow in the past year.
- Of the past 5 years IBT 4 years were profitable.
- IBT had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
- With an excellent Return On Assets value of 22.64%, IBT belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
- IBT has a better Return On Equity (28.25%) than 100.00% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 6.83%, IBT belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for IBT is in line with the industry average of 11.23%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 22.64% | ||
| ROE | 28.25% | ||
| ROIC | 6.83% |
ROA(3y)14.54%
ROA(5y)7.95%
ROE(3y)18.48%
ROE(5y)9.94%
ROIC(3y)9.26%
ROIC(5y)N/A
1.3 Margins
- IBT has a Profit Margin of 51.82%. This is amongst the best in the industry. IBT outperforms 100.00% of its industry peers.
- IBT's Profit Margin has improved in the last couple of years.
- IBT has a Operating Margin of 19.58%. This is amongst the best in the industry. IBT outperforms 100.00% of its industry peers.
- IBT's Operating Margin has improved in the last couple of years.
- The Gross Margin of IBT (71.29%) is better than 88.00% of its industry peers.
- In the last couple of years the Gross Margin of IBT has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.58% | ||
| PM (TTM) | 51.82% | ||
| GM | 71.29% |
OM growth 3Y11.49%
OM growth 5YN/A
PM growth 3Y41.01%
PM growth 5YN/A
GM growth 3Y6.79%
GM growth 5Y12.72%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), IBT is creating some value.
- IBT has less shares outstanding than it did 1 year ago.
- The debt/assets ratio for IBT has been reduced compared to a year ago.
2.2 Solvency
- IBT has an Altman-Z score of 4.22. This indicates that IBT is financially healthy and has little risk of bankruptcy at the moment.
- IBT has a better Altman-Z score (4.22) than 92.00% of its industry peers.
- IBT has a debt to FCF ratio of 1.60. This is a very positive value and a sign of high solvency as it would only need 1.60 years to pay back of all of its debts.
- The Debt to FCF ratio of IBT (1.60) is better than 96.00% of its industry peers.
- A Debt/Equity ratio of 0.10 indicates that IBT is not too dependend on debt financing.
- IBT's Debt to Equity ratio of 0.10 is in line compared to the rest of the industry. IBT outperforms 52.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 1.6 | ||
| Altman-Z | 4.22 |
ROIC/WACC0.89
WACC7.68%
2.3 Liquidity
- A Current Ratio of 5.08 indicates that IBT has no problem at all paying its short term obligations.
- Looking at the Current ratio, with a value of 5.08, IBT is in the better half of the industry, outperforming 76.00% of the companies in the same industry.
- IBT has a Quick Ratio of 4.97. This indicates that IBT is financially healthy and has no problem in meeting its short term obligations.
- With a decent Quick ratio value of 4.97, IBT is doing good in the industry, outperforming 72.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.08 | ||
| Quick Ratio | 4.97 |
3. Growth
3.1 Past
- IBT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 139.95%, which is quite impressive.
- The Earnings Per Share has been growing by 59.15% on average over the past years. This is a very strong growth
- The Revenue has decreased by -0.82% in the past year.
- Measured over the past years, IBT shows a quite strong growth in Revenue. The Revenue has been growing by 9.64% on average per year.
EPS 1Y (TTM)139.95%
EPS 3Y59.15%
EPS 5YN/A
EPS Q2Q%20.09%
Revenue 1Y (TTM)-0.82%
Revenue growth 3Y12.87%
Revenue growth 5Y9.64%
Sales Q2Q%17.51%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 9.00 indicates a reasonable valuation of IBT.
- 100.00% of the companies in the same industry are more expensive than IBT, based on the Price/Earnings ratio.
- IBT's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.47.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9 | ||
| Fwd PE | N/A |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of IBT indicates a rather cheap valuation: IBT is cheaper than 96.00% of the companies listed in the same industry.
- IBT's Price/Free Cash Flow ratio is rather cheap when compared to the industry. IBT is cheaper than 92.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 34.47 | ||
| EV/EBITDA | 14.11 |
4.3 Compensation for Growth
- IBT has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
- IBT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX-V:IBT (4/5/2024, 7:00:00 PM)
1.44
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)12-15 2021-12-15
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap35.30M
Revenue(TTM)7.80M
Net Income(TTM)4.04M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9 | ||
| Fwd PE | N/A | ||
| P/S | 4.53 | ||
| P/FCF | 34.47 | ||
| P/OCF | 15.87 | ||
| P/B | 2.47 | ||
| P/tB | 2.47 | ||
| EV/EBITDA | 14.11 |
EPS(TTM)0.16
EY11.11%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.04
FCFY2.9%
OCF(TTM)0.09
OCFY6.3%
SpS0.32
BVpS0.58
TBVpS0.58
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 22.64% | ||
| ROE | 28.25% | ||
| ROCE | 9.74% | ||
| ROIC | 6.83% | ||
| ROICexc | 15.45% | ||
| ROICexgc | 15.45% | ||
| OM | 19.58% | ||
| PM (TTM) | 51.82% | ||
| GM | 71.29% | ||
| FCFM | 13.13% |
ROA(3y)14.54%
ROA(5y)7.95%
ROE(3y)18.48%
ROE(5y)9.94%
ROIC(3y)9.26%
ROIC(5y)N/A
ROICexc(3y)24.64%
ROICexc(5y)N/A
ROICexgc(3y)24.64%
ROICexgc(5y)N/A
ROCE(3y)13.2%
ROCE(5y)N/A
ROICexgc growth 3Y5.1%
ROICexgc growth 5YN/A
ROICexc growth 3Y5.1%
ROICexc growth 5YN/A
OM growth 3Y11.49%
OM growth 5YN/A
PM growth 3Y41.01%
PM growth 5YN/A
GM growth 3Y6.79%
GM growth 5Y12.72%
F-Score6
Asset Turnover0.44
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 1.6 | ||
| Debt/EBITDA | 0.69 | ||
| Cap/Depr | 254.79% | ||
| Cap/Sales | 15.38% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 111.33% | ||
| Profit Quality | 25.34% | ||
| Current Ratio | 5.08 | ||
| Quick Ratio | 4.97 | ||
| Altman-Z | 4.22 |
F-Score6
WACC7.68%
ROIC/WACC0.89
Cap/Depr(3y)113.33%
Cap/Depr(5y)77.81%
Cap/Sales(3y)6.8%
Cap/Sales(5y)4.77%
Profit Quality(3y)120.06%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)139.95%
EPS 3Y59.15%
EPS 5YN/A
EPS Q2Q%20.09%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-0.82%
Revenue growth 3Y12.87%
Revenue growth 5Y9.64%
Sales Q2Q%17.51%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-28.47%
EBIT growth 3Y25.85%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-19.16%
FCF growth 3Y-0.7%
FCF growth 5Y47.39%
OCF growth 1Y42.74%
OCF growth 3Y17.98%
OCF growth 5Y59.75%
IBEX TECHNOLOGIES INC / IBT.CA FAQ
Can you provide the ChartMill fundamental rating for IBEX TECHNOLOGIES INC?
ChartMill assigns a fundamental rating of 6 / 10 to IBT.CA.
What is the valuation status of IBEX TECHNOLOGIES INC (IBT.CA) stock?
ChartMill assigns a valuation rating of 5 / 10 to IBEX TECHNOLOGIES INC (IBT.CA). This can be considered as Fairly Valued.
What is the profitability of IBT stock?
IBEX TECHNOLOGIES INC (IBT.CA) has a profitability rating of 8 / 10.
What is the valuation of IBEX TECHNOLOGIES INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for IBEX TECHNOLOGIES INC (IBT.CA) is 9 and the Price/Book (PB) ratio is 2.47.